Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration in the CNS typically produces progressive and profound disability-ultimately leading to death in nearly all cases. Improvement in outcome has been elusive despite decades of intensive clinical and laboratory research. Surgery and radiotherapy, the traditional cornerstones of therapy, provide palliative benefit, while the value of chemotherapy has been marginal and controversial. Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress. A novel chemoradiotherapy approach, consisting of temozolomide administered concurrently during radiotherapy followed by adjuvant systemic temozolomide, has recently demonstrated a meaningful, albeit modest, improvement in overall survival for newly diagnosed GBM patients. As cell-signaling alterations linked to the development and progression of gliomas are being increasingly elucidated, targeted therapies have rapidly entered preclinical and clinical evaluation. Responses to therapies that function via DNA damage have been associated with specific mediators of resistance that may also be subject to targeted therapies. Other approaches include novel locoregional delivery techniques to overcome barriers of delivery. The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.
INTRODUCTION
Primary CNS tumors arise in more than 41,000 people in the United States annually, and account for 1.35% of all cancers, and 2.2% of all cancer-related deaths. 1 Worldwide, approximately 176,000 cases of CNS cancer are diagnosed per year with an estimated annual mortality of 128,000. 2 Glial tumors represent 42% of all primary CNS neoplasms, and over three quarters are malignant.
3 Malignant gliomas remain one of the greatest challenges in oncology today. In a recent population-based study, overall survival of patients with newly diagnosed glioblastoma multiforme (GBM), the most common malignant glioma, was 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years, despite access to state-of-the-art surgery, imaging, radiotherapy, and chemotherapy. 4 Furthermore, the incidence of malignant gliomas may be increasing, particularly among the elderly, 5, 6 and the elucidation of pathogenic or predisposing factors remains a high priority, as these are largely unknown.
7-10

EMERGING MOLECULAR-CLINICAL CORRELATES
Malignant gliomas, like most aggressive cancers, exhibit aberrant proliferation, diminished apoptosis, avoidance of both external growth control and immunoregulation, and striking rates of de novo and acquired resistance to therapeutic intervention. An enigmatic and unique behavioral feature, however, is a nearly absent rate of metastatic dissemination beyond the CNS, despite highly robust invasive and angiogenic capabilities. Another distinguishing characteristic is marked histopathologic and genetic heterogeneity across and within tumors.
11,12
Many molecular genetic abnormalities associated with phenotypic features are being increasingly characterized and include multiple abnormalities that span several critical regulatory arenas, such as genomic instability, cell cycle control, and intracellular communication via signal transduction pathways. 13 Disruption of p53 function, a key regulator of genomic stability, occurs frequently in malignant glioma due to either direct mutation or loss, [14] [15] [16] p14 ARF mutation 17, 18 or human double-minute 2 (HDM2) amplification. [19] [20] [21] [22] Additional genetic abnormalities contribute to dysregulation of cell cycle control, including CDK4 amplification or loss of either RB1, p16INK4A or P15INK4B, due to either inactivating mutation or promoting hypermethylation. [23] [24] [25] [26] [27] [28] Malignant gliomas also frequently exhibit abnormalities of signal transduction pathways that control key cellular processes including proliferation, angiogenesis, apoptosis, and invasion. Dysregulation of the PI3K/ AKT pathway, the most prominent abnormal signaling cascade, 29,30 is associated with adverse outcome 31 and has been linked with two primary, triggering genetic defects. First, increased activity of growth factor receptor tyrosine kinases (TKIs), due to receptor overexpression, amplification, or mutation, can increase PI3K/AKT activity. The most common abnormally active growth factor TKIs in malignant gliomas include the epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR), c-kit, and insulin-like growth factor-1 receptor (IGF1R). [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] The most common EGFR mutation in malignant glioma, EGFRvIII, is created by intragenic deletion of exons 2 to 7, and exhibits ligand independent, constitutive signaling. [42] [43] [44] A second genetic defect linked with aberrant PI3K/AKT signaling is loss of the tumor suppressor gene, and negative regulator of AKT, phosphatase, and tensin homolog deleted on chromosome 10 (PTEN), which occurs in approximately 30% of GBM tumors. [45] [46] [47] [48] [49] [50] [51] Traditionally, GBMs are classified into either primary or secondary subtypes based on clinical and genetic features (Fig 1) , although morphologic and microscopic characteristics of both subtypes are indistinguishable. Primary GBMs, which account for 95% of cases, arise de novo after a short clinical history, typically affect older patients, exhibit a male predominance, and frequently display aberrant PI3K/AKT signaling due to EGFR overexpression or PTEN loss.
In contrast, secondary GBMs are relatively rare, arise from preexisting lower grade gliomas, are more commonly seen in younger patients, exhibit a female predominance, and are characterized at the molecular level by mutation of TP53 and RB1, as well as either amplification or increased expression of PDGFR. 4, 11 Of note, a recent population-based analysis revealed that the most common genetic abnormality in newly diagnosed GBM patients is loss of the distal region of chromosome 10q. This finding occurs with equal frequency among both primary and secondary GBMs. Furthermore, in this extensive analysis, loss of distal 10q was the only genetic abnormality shown to confer a negative prognosis independent of clinical factors. 4 
MULTIMODALITY THERAPY: HISTORICAL PERSPECTIVE
Patient prognosis has been based on clinical factors historically. The Radiation Therapy Oncology Group (RTOG) utilized a recursive partitioning analysis of 1,578 patients enrolled on three consecutive RTOG studies to define six prognostic patient subsets by algorithmic integration of age, histology, mental status, symptom duration, degree of surgery, and neurologic deficit. 52, 53 Recently, gene-expression and proteome-profiling analyses have been explored as strategies to more accurately predict prognosis, [54] [55] [56] [57] [58] [59] [60] [61] although such approaches will clearly require validation in prospectively followed and uniformally treated patients.
Surgery and radiotherapy (XRT), traditional cornerstones of malignant glioma therapy, provide palliative survival benefit.
62-64 Until recently, the benefit of additional chemotherapy has been negligible for most patients, with survival under 12 months for newly diagnosed GBM patients, and only 2 to 3 years for those with WHO grade 3 malignant gliomas such as anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and mixed anaplastic gliomas.
65-67 Two fundamental factors have critically hindered therapy responsiveness historically, and remain major obstacles for current and future treatments. The first critical factor is limited delivery. The blood brain barrier (BBB), although disrupted in regions of macroscopic tumor, is more intact in regions of microscopic tumor infiltration, 68,69 and stringently limits CNS access based on chemical constitution and size. 70, 71 In addition, BBB efflux proteins, such as P-glycoprotein A second critical determinant of therapy efficacy is marked cellular and genetic heterogeneity across, and within, these tumors. Malignant gliomas, in particular GBM, have been long associated with striking histologic heterogeneity.
11,12 Another measure of tumor heterogeneity-cell surface protein expression-varies dramatically among and within tumors. 84, 85 Furthermore, molecular defects, many of which are now being targeted by cutting edge therapies, also exhibit striking patterns of heterogeneity across and within tumors.
30,31,37,86-88 Thus, inter-and intratumoral heterogeneity likely represents an evolved defense mechanism of malignant gliomas, that not only poses a significant therapeutic challenge, particularly in the monotherapy setting, but also complements the prevalent, additional de novo and acquired resistance mechanism frequently exhibited by these tumors including O 6 -alkylguanine-DNA alkyltransferase (AGT), nucleotide excision repair, and deficiency of mismatch repair.
89-98 Furthermore, recently identified CD133ϩ, tumorigenic neural stem cells may exhibit a completely different profile of treatment responsiveness compared with that of the non-stem-cell tumor population, thereby potentially adding an additional level of complexity to this challenging issue.
99-103
Recent therapeutic advances have led to modest improvement in outcome for some malignant glioma patients, while additional developing approaches, offer additional promise. Nonetheless, efforts to overcome the fundamental challenges posed by limited delivery and tumor heterogeneity are likely to offer great potential impact on future progress.
TEMOZOLOMIDE: A NEW STANDARD OF CARE
Temozolomide (TMZ), a second generation imidazotetrazine derivative, methylates specific DNA sites, the most critical being the O 6 position of guanine. 104 Nucleotide mismatch between complementary strands triggers continuous cycles of futile mismatch repair, that in turn, ultimately induce apoptosis.
105,106 Several characteristics make TMZ an attractive therapeutic for brain tumor patients including that it (1) readily crosses the BBB and achieves CSF concentrations that are approximately 40% of plasma; (2) is nearly100% bioavailable after oral dosing; (3) does not require hepatic metabolism for activation; (4) exhibits dose-linear pharmacokinetics with little intrasubject or intersubject variability; and (5) is associated with generally mild and predictable toxicity.
107,108
Promising initial results (Table 1) led to accelerated approval of TMZ in 1999 for the treatment of recurrent AA in the United States, and approval in Europe for the treatment of recurrent AA and GBM, [109] [110] [111] [112] as well as the evaluation of TMZ among newly-diagnosed GBM patients. In the first such study, 17 of 33 patients with newlydiagnosed and untreated GBM (51%) achieved a radiographic response following TMZ administered before conventional XRT (200 mg/m 2 /d for 5 days every 28 days for up to four cycles). 92 Three subsequent, open-label studies, enrolling a total of 767 patients, were recently performed to evaluate a novel combinatorial approach that included continuous, oral TMZ dosing administered concurrently with XRT, followed by monthly cycles of adjuvant TMZ (Table 2) . Importantly, however, patient characteristics were comparable between arms of each randomized study.
Compliance with prescribed therapy was good across the studies, reflecting the limited toxicity of the treatment regimens. The most common adverse effects associated with TMZ administration were hematologic ( Table 2 ). Severe infections were infrequent and additional, nonhematologic toxicities were mild to moderate in most cases and included nausea/emesis, rash, constipation, and fatigue. Adjuvant TMZ discontinuation or dose modification was required in 8% to 25%, and 40% to 60% of patients received six cycles. Although not described in any of these studies, two concerning recent reports TMZ improved outcome on all three chemoradiotherapy studies although lower survivals were observed on the Athanassiou study, probably reflecting the comparatively poorer patient characteristics. The median overall survival for patients treated with TMZ was significantly better than that achieved with XRT alone on both randomized studies. In addition, the difference in survival between patients treated with XRT compared with TMZ/XRT-TMZ widened with time from diagnosis. The 18-month survival rate on the Athanassiou study was 25% for patients treated with TMZ/XRT-TMZ compared with only 5% survival for those treated with XRT alone. Similarly, the 24-month survival rate on the phase III EORTC/NCIC study was 27% for the TMZ/XRT-TMZ group compared with only 10% for the XRT group. Furthermore, evaluation of outcome on these studies relative to established prognostic features suggests that TMZ improves outcome in nearly all patient subsets. Of note, patients with poor performance status were the only subset treated with TMZ/XRT-TMZ who did not achieve a statistically significant improvement in OS in the EORTC/ NCIC study.
The combined data from these trials indicates that the TMZ/ XRT-TMZ regimen should be considered a new standard of care for newly diagnosed GBM patients. However, a number of issues require clarification if we are to effectively build on these results. First, a better understanding of this regimen's mechanism of activity, particularly the interaction of TMZ with XRT, is clearly needed. Second, what is the relative value of each TMZ component to the overall TMZ/XRT-TMZ regimen? In particular, does adjuvant TMZ benefit all or only some patients beyond that of TMZ with XRT? The fact that outcome was poorer among patients treated on the EORTC/NCIC study with XRT alone, despite TMZ administration to most patients at relapse, suggests that TMZ during XRT is a particularly important component of the TMZ/XRT-TMZ regimen. A related controversy is whether the data from the GBM chemoradiotherapy studies should be extrapolated to define a new standard of care for newly diagnosed grade 3 malignant glioma patients. The results of two RTOG studies may help resolve this controversy. Although the chemoradiotherapy GBM study results are highly significant and provide an important step forward, the overall benefit achieved with the TMZ/XRT-TMZ regimen, is modest. Specifically, median progression-free survival for patients treated with TMZ/XRT-TMZ on the pivotal EORTC/NCIC study was under 7 months, and OS was under 15 months. Clearly we still have a long way to go. Two additional courses of action may lead to additional incremental advances. First, modifications of the TMZ/XRT-TMZ regimen should be explored that may heighten its efficacy. Potential options to do so include alternative dosing schedules, 119,120 longer durations of therapy, 123 strategies to enhance delivery, and the addition of agents with complementary mechanisms of antitumor activity such as additional cytotoxics, targeted therapeutics (discussed in the section Targeted Therapies: Current Focus of Clinical Development), and locally administered agents (also discussed in the section Advances in Locoregional Therapy).
A second important step is the determination of biologic factors that identify subsets of patients with predictable response (or lack thereof) to TMZ/XRT-TMZ. An example of a biomarker predictive of treatment response is chromosomal 1p and 19q tumor deletion among anaplastic oligodendroglioma patients. 124 While much work remains to develop biomarkers that can reliably predict response among malignant glioma patients, one clearly important modulator of TMZ response is O 6 -alkylguanine-DNA alkyltransferase (AGT).
AGT: THE NEXT HURDLE
AGT is a critical DNA repair protein also referred to as O 6 -methylguanine-DNA-methyltransferase (MGMT) which removes chloroethylation or methylation damage from the O 6 position of DNA guanines, thereby protecting normal cells from exogenous carcinogens, and similarly protecting tumor cells from alkylating and methylating chemotherapeutic agents. 125 AGT levels vary significantly across and within tumor types.
126,127 Methylation of CpG islands within the AGT promoter is an epigenetic factor that can diminish AGT transcription and expression. 91 AGT levels can be most readily measured by either immunohistochemistry or by a methylationspecific PCR assay.
128-130
Friedman et al initially implicated AGT in TMZ responsiveness among malignant glioma patients. 92 In a series of 36 newly diagnosed patients, including 33 with GBM, the response rate to TMZ was 60% among patients with low-level AGT (detected by immunohistochemistry in Ͻ 20% of cells) compared with only 9% among patients with high-level AGT (present in Ն 20% of tumor cells). Similarly, following carmustine (BCNU) chemotherapy, Estellar noted a radiographic response in 12 (64%) of 19 malignant glioma patients with methylated AGT compared with only 1 (4%) of 28 patients with unmethylated AGT. 91 Two subsequent, prospective studies demonstrate that AGT methylation is associated with better survival among malignant glioma patients treated with TMZ (Table 3) . 93, 94 Of note, in these studies, the Kaplan-Meier survival curves for patients with methylated and unmethylated AGT become particularly divergent after 12 months of follow-up. Furthermore, these studies suggest that tumor AGT status is an independent predictor of outcome following therapy with alkylator-based chemotherapy, because AGT status does not correlate with established clinical prognostic factors.
Therefore a looming, fundamental question is whether tumor AGT status should ultimately direct treatment of newly diagnosed GBM patients. Although results to date suggest that AGT status is an important biomarker for TMZ responsiveness, these findings require further validation in additional prospective analyses. One important factor supporting such validation is that less than half of all samples analyzed in the landmark Hegi study 94 were informative of AGT status. In addition, controversy exists regarding the optimal technique to assess tumor AGT status. Validated, commercially-available, PCRbased AGT methylation assays are not yet approved for clinical use, and may be technically challenging. Furthermore, inactivation of AGT transcription can occur by cytosine methylation of discrete regions of CG dinucleotide islands 129 and additional study may be required to identify which methylation regions are most predictive of potential gene silencing. Immunohistochemical techniques are more widely available, but may be less reliable since external factors such as glucocorticoids, XRT, and genotoxic agents, can influence AGT expression.
131,132 Therefore, pending validation of AGT testing in additional, prospective GBM clinical trials, and the development of a validated, -methylguanine-DNA-methyltransferase; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; NA, not available.
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www.jco.orgcommercially available assay, it is premature to routinely incorporate AGT status in directing GBM therapy. Although it appears clear that TMZ should be an integral component of therapy for patients with low AGT tumors, two fundamental questions remain. First, can the TMZ/XRT regimen be successfully modified to improve outcome for good prognosis patients (defined by either low AGT or methylated AGT) knowing that the median survival for this patient subset is under 22 months following treatment with TMZ/XRT-TMZ? 94 Second, should TMZ be excluded in the treatment of patients with high AGT or unmethylated AGT, particularly given its cost 133 and potential toxicity? One potential strategy to ameliorate AGT-mediated chemoresistance is to incorporate TMZ into therapeutic regimens that include AGT inactivating agents, such as O 6 -benzylguanine. 134, 135 In addition, given the heterogeneity of AGT expression within individual tumors, a portion of the overall tumor burden may be AGT deficient and therefore TMZ sensitive. It is reasonable therefore to consider TMZ for AGT positive patients in combinatorial regimens that include agents that are either AGT suppressing, or are unaffected by AGT. Clearly additional studies are required to address these important issues.
ADVANCES IN LOCOREGIONAL THERAPY
The rationale for locoregionally administered therapies for malignant glioma patients is based on three fundamental factors. First, locally administered therapeutics may circumvent the BBB and thus potentially achieve higher intratumoral concentrations than are achievable following systemic administration. Second, systemic exposures associated with locoregional therapies are typically minimal, leading to less systemic toxicity. Third, since the majority of malignant gliomas recur at the primary tumor site, 136,137 locoregional therapeutics may improve local control and thus improve overall outcome.
Gliadel, the initial locoregional therapy approved for malignant glioma patients, provides sustained delivery of BCNU from a controlled release, biodegradable polymer placed around the resection perimeter at surgery.
138 Double-blind, randomized, placebocontrolled studies demonstrate that Gliadel improves survival for patients with either recurrent GBM or newly diagnosed malignant glioma.
139,140 These encouraging results have led to additional investigations. In a recent phase I study, the maximum tolerated dose of BCNU delivered via biodegradable polymer was determined to be 20%, approximately five times greater than that utilized in the current formulation. 141 Ongoing studies are evaluating the clinical activity of a higher concentration, BCNU polymer preparation. In addition, studies have confirmed that Gliadel can be safely combined with systemically administered agents, such as TMZ.
142 Furthermore, the polymer delivery approach is currently being adopted to investigate delivery of a wide variety of additional therapeutic agents including alternative chemotherapeutics, angiogenesis inhibitors, radiosensitizers, immunomodulators, and cytokines. 143 Another locoregional strategy is the delivery of increased radiation to the tumor bed. One approach-stereotactic radiosurgeryhas been shown to not improve outcome in a randomized phase III study. 144 Another approach, brachytherapy with 125 I-beads implanted into the resection cavity, has improved outcome compared with historical controls, but is associated with a high rate of radiation necrosis requiring surgical debulking.
145-147 A third approach, 152,153 Additional molecular targets currently under investigation for antibody-toxin, antibody-chemotherapeutic agent, or radioimmunotherapy include glycoprotein neuromedin B, MRP3, a member of the multidrug resistance family, the gangliosides 3ЈisoLM1 and 3Ј6Ј-isoLD1, the insulin growth factor receptor and wild type and variant III epidermal growth factor receptor. Encouraging survival benefit has been noted in single arm studies evaluating the administration of radiolabeled antitenascin MAb into the resection cavity of newly diagnosed and recurrent malignant glioma patients, with a low rate of radiation necrosis requiring surgical debulking. [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] Randomized studies are planned to further evaluate radioimmunotherapy approaches.
The use of convection enhanced delivery (CED) is another innovative locoregional therapeutic intervention currently being widely evaluated for malignant glioma patients. CED utilizes microinfusion catheters strategically placed with stereotactic guidance in the peritumoral region to gradually infuse a therapeutic over 3 to 5 days. By applying a consistent, pressure-gradient, CED can overcome limitations associated with diffusion and elevated intratumoral interstitial pressures 82 and potentially deliver therapeutic agents homogeneously into clinically significant volumes of distribution (Fig 2A) . 164 A variety of therapeutics have been evaluated including chemotherapeutics, 165 ,166 liposomal gene vector particles 167 and tumor-targeting toxin conjugates.
168-174 Tumor-targeting toxin conjugates represent a novel development that are particularly well-suited for CED ( Fig  2B) . 175 These genetically engineered agents, composed of a tumor cell receptor ligand conjugated to a highly potent toxin moiety (Table 4) , have been associated with encouraging long-term survivals.
176,177
Large, multicenter, randomized clinical trials are ongoing to further define the role of toxin conjugates delivered via CED.
TARGETED THERAPIES: CURRENT FOCUS OF CLINICAL DEVELOPMENT
Cancer cells frequently exploit critical molecules and signal transduction pathways to drive aberrant proliferation, invasion, angiogenesis, and survival. [178] [179] [180] Molecularly targeted agents are being developed as potential, selective inhibitors of these molecules and pathway components. Several such agents have confirmed antitumor benefit and are currently integrated into treatment algorithms for a variety of cancers, including imatinib (Bcr-Abl, platelet-derived growth factor, and c-KIT inhibitor for chronic myelogenous leukemia and gastrointestinal stromal tumors), 181,182 bevacizumab (humanized antivascular endothelial growth factor monoclonal antibody for colorectal cancer), 183 erlotinib (epidermal growth factor receptorinhibitor for lung cancer), 184 and trastuzumab (Her-2-neu monoclonal antibody for breast cancer). 185 The role of molecular targeted agents for malignant glioma patients remains to be determined. On the one hand, malignant gliomas harbor a wide array of molecular defects, yielding a large number of potentially exploitable, therapeutic targets (Fig 3; Table 5 ). On the other hand, given the diversity and number of molecular defects in these tumors, as well as the known redundancy and cross-talk between aberrant signal transduction pathways, one would predict that inhibition of a single target is unlikely to have a major, durable antitumor effect for most malignant glioma patients. Results of first generation clinical trials, conducted to evaluate a wide array of molecular targeted agents as monotherapeutics, support this prediction. [186] [187] [188] [189] [190] [191] In fairness, however, additional factors may have also contributed to the limited activity observed in these trials, including impaired CNS delivery, altered pharmacokinetic metabolism due to concurrently administered medications, such as CYP3A-inducing antiepileptics, [192] [193] [194] [195] and inadequate intratumoral concentration to effectively inhibit the intended target.
Nonetheless, subsets of patients have derived encouraging clinical benefit in some trials. For example, eight (20%) of 41 patients responded to the EGFR tyrosine kinase inhibitor (TKI) erlotinib in a recently reported phase I trial, 187 while seven (13%) of 53 recurrent GBM patients remained progression-free for at least 6 months in response to an alternative EGFR TKI, gefitinib.
186 Activating EGFR mutations, associated with response to EGFR TKIs in some lung cancer patients [196] [197] [198] have not been identified to date in GBM patients, [199] [200] [201] [202] suggesting that alternative mechanisms underlie response in these patients.
Characterization of PI3K/AKT pathway components from archival tumor specimens has identified subsets of malignant glioma patients who may preferentially respond to EGFR TKI therapy. 187, 202 In addition, preclinical studies suggest that combinatorial regimens of targeted therapeutics may be markedly more effective than single agent strategies in malignant glioma. Particularly effective combinations may simultaneously inhibit either cell surface and intracellular components of a critical signal transduction pathway (such as an EGFR TKI plus an mTOR inhibitor) or integral components of parallel pathways. [203] [204] [205] Such combinatorial approaches are now being investigated in second generation clinical trials for malignant glioma patients. In addition, clinical trials are ongoing that combine molecular-targeted agents with cytotoxic agents including XRT and chemotherapy, based on preclinical data demonstrating enhanced activity of such combinations.
31,206-209 A novel clinical trial paradigm currently being applied includes pharmacodynamic assessments performed on tumor tissue obtained at scheduled surgery following an upfront window of targeted agent therapy. Results from such studies will provide important insight into the ability of these agents to overcome delivery obstacles and inhibit the intended target, as well as guide the design of treatment regimens to more effectively overcome challenges posed by tumor heterogeneity.
CONCLUSION
The emergence of temozolomide as an effective therapy for malignant glioma patients, and the development of innovative therapies designed to circumvent treatment resistance, augment delivery, and block critical, tumor associated targets, marks a new era in neurooncology. The nihilism from 30 years of diligent, dedicated research failing to impact patient survival, is gradually giving way to a budding, cautious optimism that we are indeed on the verge of meaningful strides for patients with these tumors. Critical challenges persist. An immediate question is how to most effectively build on the activity demonstrated in the TMZ/XRT-TMZ chemoradiotherapy trials. Can we modify this regimen to enhance its activity? Can we take advantage of our growing knowledge of the impact of TMZ resistance mechanisms, such as AGT, to better identify patient subsets for more effective treatment? Finally, the fundamental challenges posed by limited effective delivery and tumor heterogeneity, must be overcome if additional progress is to be realized. Locoregional therapeutics and molecularly-targeted therapies represent strategies that may help overcome these longstanding hurdles. Additional exploration of these important issues, through ongoing laboratory and clinical research, will no doubt continue to move us forward. Also inhibits PDGFR, c-kit and raf GW786034 Also inhibits PDGFR and c-kit AZ2171 ZD6474 Also inhibits EGFR Abbreviations: VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor; PKC, protein kinase C; VEGF, vascular endothelial growth factor. and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am 
